News

Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

Forex Daily Briefing

US Markets

Stocks To Watch

The Week Ahead

SECTOR NEWS

Commodites

Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News

Newswires

OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

Veracyte Hikes on Cancer Test Data

Veracyte, Inc. (NASDAQ: VCYT) noticed its shares rise sharply Wednesday. The company, a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.

African-American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.

The VANDAAM trial enrolled men with low- or intermediate-risk prostate cancer as classified by the National Comprehensive Cancer Network (NCCN) Guidelines® for Prostate Cancer. For the current analysis, researchers evaluated data for a clinically balanced cohort of 226 men (113 African American men and 113 non-African American men) and performed genomic analysis using the Decipher Prostate classifier to generate Decipher risk scores

VCYT shares took on 30 cents to $33.93.